Not checked for notices yet.

Are localized prostate cancer biomarkers useful in the clinical practice?

Arie Carneiro, Paulo Priante Kayano, Álan Roger Gomes Barbosa and 8 more

Tumor Biology · 2018

doi:10.1177/1010428318799255

References 79

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer · 2009
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy · 2013
No notice
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies · 2013
No notice
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden · 2008
No notice
52.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort · 2012
No notice
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
57.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
58.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
59.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
60.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
61.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
62.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
63.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
64.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
65.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
66.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
67.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
68.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
69.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
70.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
71.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
72.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
73.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
74.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
75.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
76.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
77.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
78.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
79.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.